Shares of Purple Biotech Ltd (PPBT) are falling about 35 percent in Thursday morning trading following the company's announcement of new preclinical data from its lead CAPTN-3 program, IM1240.
The company's stock is currently trading at $1.9, down 35.73 percent, over the previous close of $2.96 on the Nasdaq. It has traded between $1.75 and $29.00 in the past one year.
IM1240 demonstrated anti-tumor activity across PD-1- and chemotherapy-resistant patient-derived tumor samples in head and neck, bladder, and lung cancers, with the NKG2A arm identified as a key contributor to this anti-tumor efficacy.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.